170 related articles for article (PubMed ID: 3350230)
21. Nephrotoxic potential of cis-diamminedichloroplatinum and four analogs in male Fischer 344 rats.
Levine BS; Henry MC; Port CD; Richter WR; Urbanek MA
J Natl Cancer Inst; 1981 Jul; 67(1):201-6. PubMed ID: 6942191
[TBL] [Abstract][Full Text] [Related]
22. Renal papillary necrosis and urinary protein alterations induced in Fischer-344 rats by D-ormaplatin.
Kolaja GJ; Packwood WH; Bell RR; Ratke CC; Stout CL
Toxicol Pathol; 1994; 22(1):29-38. PubMed ID: 8073221
[TBL] [Abstract][Full Text] [Related]
23. Influence of streptozotocin (STZ)-induced diabetes, dextrose diuresis and acetone on cisplatin nephrotoxicity in Fischer 344 (F344) rats.
Scott LA; Madan E; Valentovic MA
Toxicology; 1990; 60(1-2):109-25. PubMed ID: 2107603
[TBL] [Abstract][Full Text] [Related]
24. Nephrotoxicity of a new platinum compound, 254-S, evaluated with rat kidney cortical slices.
Kameyama Y; Okazaki N; Nakagawa M; Koshida H; Nakamura M; Gemba M
Toxicol Lett; 1990 Jun; 52(1):15-24. PubMed ID: 2356567
[TBL] [Abstract][Full Text] [Related]
25. Organic anion transporter 5 (Oat5) renal expression and urinary excretion in rats treated with cisplatin: a potential biomarker of cisplatin-induced nephrotoxicity.
Bulacio RP; Torres AM
Arch Toxicol; 2013 Nov; 87(11):1953-1962. PubMed ID: 23649842
[TBL] [Abstract][Full Text] [Related]
26. Effects of diethyldithiocarbamate (DDTC) on the plasma biotransformations of tetrachloro(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in Fischer 344 rats.
Carfagna PF; Wyrick SD; Holbrook DJ; Chaney SG
J Biochem Toxicol; 1991; 6(1):71-80. PubMed ID: 1652641
[TBL] [Abstract][Full Text] [Related]
27. Comparative nephrotoxicity of carboplatin and cisplatin in combination with tobramycin.
Bregman CL; Williams PD
Cancer Chemother Pharmacol; 1986; 18(2):117-23. PubMed ID: 3539384
[TBL] [Abstract][Full Text] [Related]
28. Urinary protein and enzyme excretion in patients receiving chemotherapy with the cis-platinum analogs carboplatin (CBDCA, JM8) and iproplatin (CHIP, JM9).
Skillen AW; Buamah PK; Cantwell BM; Cornell C; Hodson AW; Harris AL
Cancer Chemother Pharmacol; 1988; 22(3):228-34. PubMed ID: 3044631
[TBL] [Abstract][Full Text] [Related]
29. Protective effect of piperacillin against the nephrotoxicity of cisplatin in rats.
Hayashi T; Watanabe Y; Kumano K; Kitayama R; Muratani T; Yasuda T; Saikawa I; Katahira J; Kumada T; Shimizu K
Antimicrob Agents Chemother; 1989 Apr; 33(4):513-8. PubMed ID: 2729945
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of gamma-glutamyl transpeptidase or cysteine S-conjugate beta-lyase activity blocks the nephrotoxicity of cisplatin in mice.
Townsend DM; Hanigan MH
J Pharmacol Exp Ther; 2002 Jan; 300(1):142-8. PubMed ID: 11752109
[TBL] [Abstract][Full Text] [Related]
31. Rapid reduction of tetrachloro(D,L-trans)1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in RPMI 1640 tissue culture medium.
Gibbons GR; Wyrick S; Chaney SG
Cancer Res; 1989 Mar; 49(6):1402-7. PubMed ID: 2924297
[TBL] [Abstract][Full Text] [Related]
32. Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity.
Goren MP; Forastiere AA; Wright RK; Horowitz ME; Dodge RK; Kamen BA; Viar MJ; Pratt CB
Cancer Chemother Pharmacol; 1987; 19(1):57-60. PubMed ID: 2880677
[TBL] [Abstract][Full Text] [Related]
33. Effect of oral administration of Arabic gum on cisplatin-induced nephrotoxicity in rats.
Al-Majed AA; Abd-Allah AR; Al-Rikabi AC; Al-Shabanah OA; Mostafa AM
J Biochem Mol Toxicol; 2003; 17(3):146-53. PubMed ID: 12815610
[TBL] [Abstract][Full Text] [Related]
34. Interaction of 11 cisplatin analogues with DNA: characteristic pattern of damage with monofunctional analogues.
Murray V; Whittaker J; Temple MD; McFadyen WD
Biochim Biophys Acta; 1997 Nov; 1354(3):261-71. PubMed ID: 9427535
[TBL] [Abstract][Full Text] [Related]
35. Comparative studies on nephrotoxic effects of tris (2,3-dibromopropyl) phosphate and bis (2,3-dibromopropyl) phosphate on rat urinary metabolites.
Fukuoka M; Takahashi T; Naito K; Takada K
J Appl Toxicol; 1988 Feb; 8(1):43-52. PubMed ID: 3356864
[TBL] [Abstract][Full Text] [Related]
36. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
Mellish KJ; Kelland LR; Harrap KR
Br J Cancer; 1993 Aug; 68(2):240-50. PubMed ID: 8347478
[TBL] [Abstract][Full Text] [Related]
37. Organ-specific biotransformation of ormaplatin in the Fischer 344 rat.
Thompson DC; Vaisman A; Sakata MK; Wyrick SD; Holbrook DJ; Chaney SG
Cancer Chemother Pharmacol; 1995; 36(5):439-47. PubMed ID: 7634386
[TBL] [Abstract][Full Text] [Related]
38. Comparison of intestinal toxic effects of platinum complexes: cisplatin (CDDP), carboplatin (CBDCA), and iproplatin (CHIP).
Kralovánszky J; Prajda N; Kerpel-Fronius S; Gál F; Kiss F
Cancer Chemother Pharmacol; 1988; 21(1):40-4. PubMed ID: 3277733
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of cis-diamminedichloroplatinum (II)--induced renal toxicity in the rat.
Jones MM; Basinger MA; Mitchell WM; Bradley CA
Cancer Chemother Pharmacol; 1986; 17(1):38-42. PubMed ID: 3698175
[TBL] [Abstract][Full Text] [Related]
40. Comparison of methods of evaluating nephrotoxicity of cis-platinum.
Jones BR; Bhalla RB; Mladek J; Kaleya RN; Gralla RJ; Alcock NW; Schwartz MK; Young CW; Reidenberg MM
Clin Pharmacol Ther; 1980 Apr; 27(4):557-62. PubMed ID: 6987030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
